Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Randolph P Matthews

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Journal of Pharmaceutical and Biomedical Analysis|February 17, 2022
Incorporating protein precipitation to resolve hybrid IP-LC-MS assay interference for ultrasensitive quantification of intact therapeutic insulin dimer in human plasmaLi Sun, Yang Xu, Neal Dube, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 15, 2021
Safety and Pharmacokinetics of Once-Daily Multiple-Dose Administration of Islatravir in Adults Without HIVRandolph P Matthews, Deanne Jackson Rudd, Saijuan Zhang, et al.
Plos One|October 3, 2013
CCBE1 mutation in two siblings, one manifesting lymphedema-cholestasis syndrome, and the other, fetal hydropsSohela Shah, Laura K Conlin, Luis Gomez, et al.
Gastroenterology|January 23, 2013
Evidence from human and zebrafish that GPC1 is a biliary atresia susceptibility geneShuang Cui, Melissa Leyva-Vega, Ellen A Tsai, et al.
Antimicrobial Agents and Chemotherapy|November 8, 2022
Safety and Pharmacokinetics of Islatravir in Individuals with Severe Renal InsufficiencyRandolph P Matthews, Youfang Cao, Munjal Patel, et al.
Antimicrobial Agents and Chemotherapy|January 14, 2025
Nonclinical and clinical characterization of the absorption, metabolism, and excretion of islatravirKerry L Fillgrove, Randolph P Matthews, Bing Lu, et al.
Clinical and Translational Science|August 31, 2021
Safety, tolerability, and pharmacokinetics of single- and multiple-dose administration of islatravir (MK-8591) in adults without HIVRandolph P Matthews, Wendy Ankrom, Evan Friedman, et al.
Nature Medicine|October 5, 2021
Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase 1 trialRandolph P Matthews, Munjal Patel, Stephanie E Barrett, et al.
Clinical and Translational Science|September 15, 2025
Safety and Pharmacokinetics of MK-8527 in Adults Without HIVGillian Gillespie, Russ P Carstens, Xiaowei Zang, et al.
The Lancet. HIV|January 9, 2020
Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trialDirk Schürmann, Deanne Jackson Rudd, Saijuan Zhang, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Journal of Pharmaceutical and Biomedical Analysis|February 17, 2022
Incorporating protein precipitation to resolve hybrid IP-LC-MS assay interference for ultrasensitive quantification of intact therapeutic insulin dimer in human plasmaLi Sun, Yang Xu, Neal Dube, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 15, 2021
Safety and Pharmacokinetics of Once-Daily Multiple-Dose Administration of Islatravir in Adults Without HIVRandolph P Matthews, Deanne Jackson Rudd, Saijuan Zhang, et al.
Plos One|October 3, 2013
CCBE1 mutation in two siblings, one manifesting lymphedema-cholestasis syndrome, and the other, fetal hydropsSohela Shah, Laura K Conlin, Luis Gomez, et al.
Gastroenterology|January 23, 2013
Evidence from human and zebrafish that GPC1 is a biliary atresia susceptibility geneShuang Cui, Melissa Leyva-Vega, Ellen A Tsai, et al.
Antimicrobial Agents and Chemotherapy|November 8, 2022
Safety and Pharmacokinetics of Islatravir in Individuals with Severe Renal InsufficiencyRandolph P Matthews, Youfang Cao, Munjal Patel, et al.
Antimicrobial Agents and Chemotherapy|January 14, 2025
Nonclinical and clinical characterization of the absorption, metabolism, and excretion of islatravirKerry L Fillgrove, Randolph P Matthews, Bing Lu, et al.
Clinical and Translational Science|August 31, 2021
Safety, tolerability, and pharmacokinetics of single- and multiple-dose administration of islatravir (MK-8591) in adults without HIVRandolph P Matthews, Wendy Ankrom, Evan Friedman, et al.
Nature Medicine|October 5, 2021
Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase 1 trialRandolph P Matthews, Munjal Patel, Stephanie E Barrett, et al.
Clinical and Translational Science|September 15, 2025
Safety and Pharmacokinetics of MK-8527 in Adults Without HIVGillian Gillespie, Russ P Carstens, Xiaowei Zang, et al.
The Lancet. HIV|January 9, 2020
Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trialDirk Schürmann, Deanne Jackson Rudd, Saijuan Zhang, et al.
Pageof 5